Free Trial
NASDAQ:XTLB

XTL Biopharmaceuticals 12/30/2024 Earnings Report

XTL Biopharmaceuticals EPS Results

Actual EPS
-$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XTL Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XTL Biopharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

XTL Biopharmaceuticals Earnings Headlines

Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.tc pixel
XTL Biopharmaceuticals Ltd. (XTLB) - Yahoo Finance
XTL Biopharmaceuticals names Noam Band as CEO
See More XTL Biopharmaceuticals Headlines

About XTL Biopharmaceuticals

XTL Biopharmaceuticals (NASDAQ:XTLB) engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

View XTL Biopharmaceuticals Profile

More Earnings Resources from MarketBeat